On September 4, 2018 Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, reported that its collaborator ProMab Biotechnologies, Inc. ("ProMab") will present at the CAR-TCR Summit 2018 being held from September 4th – 7th, 2018 in Boston, Massachusetts (Press release, Helix BioPharma, SEP 4, 2018, View Source [SID1234530406]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Vita Golubovskaya, Director, R&D, BD of Promab Biotechnologies will present on September 5th at 12:25pm. The title of the presentation is "Novel CAR-T Cells Against Solid and Hematological Cancers". Dr. Golubovskaya’s presentation will include certain preclinical data from the multiple myeloma project currently in collaboration with Helix.

Helix continues to aim for a possible first-in-human CAR-T study in 2019. To achieve this goal, Helix’s wholly-owned Polish subsidiary Helix Immuno-Oncology ("HIO") will be leading the preclinical and clinical development program in Poland prioritizing a possible European clinical submission. Helix and HIO are engaging experts to advise on the program and are currently securing the necessary financial resources to meet the project timelines.

On September 4, 2018 Dynavax Technologies Corporation (NASDAQ: DVAX) reported publication of a preclinical study demonstrating that inhalation of a TLR9 agonist can stimulate effective immunity against lung tumors and complement the actions of PD-1 blockade to generate durable, systemic anti-tumor immunity (Press release, Dynavax Technologies, SEP 4, 2018, View Source [SID1234530120]). The paper titled Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T cell Interplay, by Dynavax scientists M.Gallotta, H. Assi, E. Degagné, S. Kannan, R.Coffman and C. Guiducci was published in the journal Cancer Research. The study demonstrated that combining an inhaled TLR9 agonist with systemic anti-PD-1 led to long-term survival in two different mouse lung tumor models, mediated by systemic immunity that eradicated tumors both in the lung and in distal organs. The study further delineated the distinctive mechanisms of action of these agents in the lung environment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Administration of the TLR9 agonist SD-101 into the lungs of mice with metastatic tumors generated anti-tumor responses that controlled or eliminated tumor growth in the lungs as well as in non-treated organs, including liver. Treatment with SD-101 resulted in ~90% decrease in tumor burden in both the lung and liver. This led to a significant increase in survival time, with a majority of mice surviving beyond 90-100 days. Treatment with SD-101 and anti-PD-1 resulted in a large increase of tumor-reactive T cells, which were required for anti-tumor activity. The durable control of liver metastases shows that local administration of SD-101 to the lung generates an anti-tumor T cell response capable of controlling tumor growth beyond the lung itself.

The TLR9 agonist used in these studies was SD-101, Dynavax’s lead clinical candidate currently being developed as an intratumoral agent in combination with anti-PD-1 therapy in patients with advanced melanoma and head and neck squamous cell carcinoma. Unpublished data demonstrates that another TLR9 agonist, DV281 – optimized for delivery to primary lung tumors and lung metastases – has equivalent activity in these models. These studies provide the preclinical rationale for the Phase 1b dose escalation study of inhaled DV281 currently being conducted by Dynavax in advanced non-small lung cancer patients (NCT03326752). DV281 and SD-101 stimulate potent Type 1 interferon induction along with maturation of dendritic cells into effective antigen-presenting cells. These combined actions lead to the increased numbers of cytotoxic T cells that are critical for the induction of effective systemic anti-tumor immunity.

On September 4, 2018 LifeArc, one of the UK’s leading medical research charities, is delighted to announce the appointment of Melanie Lee, PhD, CBE as its new Chief Executive Officer (CEO), effective 1st November 2018 (Press release, LifeArc, SEP 4, 2018, View Source [SID1234529465]). Dave Tapolczay, the present CEO, will be retiring from his position next month after 11 years’ service.1 Melanie brings to LifeArc a wealth of leadership experience from the biopharmaceutical industry and the medical research charity sector. Her previous role as Chief Scientific Officer of BTG plc followed senior research leadership positions at Glaxo/GlaxoWellcome, Celltech plc / UCB; Non-Executive Director roles at H. Lundbeck A/S and BTG plc and currently at Sanofi, CEO roles at Syntaxin Ltd and NightstaRx Ltd and Chair and Deputy Chair Trustee appointments at Cancer Research Technology and Cancer Research UK respectively.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Explaining her reasons for accepting the CEO role Melanie said: "This is a once in a lifetime opportunity for me to join a unique charity that can create life-changing therapeutics. The innovative scientific research supported by LifeArc encompasses numerous life science sectors and has the potential to deliver great science, innovative medicines and new diagnostics to patients in need; it’s this potential that really motivates me. I am looking forward to the prospect of leading this vibrant research charity through the next phase of its development."

Melanie’s appointment has been made at a time of great opportunity for LifeArc. The charity, which evolved from Medical Research Council Technology (MRCT) in 2017, has benefitted from a significant royalty stream arising from sales of Keytruda.2 The income stream generated by Keytruda and other projects, has transformed LifeArc’s ability to fund and invest in innovative medical research and has already resulted in the creation of a dedicated Seed Fund and of a Philanthropic Fund providing rare disease research grant funding.

Commenting on the announcement, Dr John Stageman, OBE, LifeArc’s Chair, said: "We conducted a detailed and lengthy search for our new CEO and my fellow Trustees and I are delighted that Melanie has decided to join us at this most exciting time in the organisation’s history. I believe that she possesses the ideal blend of business leadership plus strategic and scientific acumen to help us deliver a bright future for LifeArc. With the addition of Melanie’s unique professional experience to our already-established senior executive team, I am confident that LifeArc can continue to evolve by turning great science into greater patient benefit."

On September 4, 2018 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that Marc N. Casper, president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018, at 2:15 p.m. (ET) at the Grand Hyatt New York, New York (Press release, Thermo Fisher Scientific, SEP 4, 2018, View Source [SID1234529458]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com.

On September 4, 2018 Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ: EGRX) reported that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Morgan Stanley 16th Annual Global Healthcare Conference as follows (Press release, Eagle Pharmaceuticals, SEP 4, 2018, View Source [SID1234529441]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday, September 13, 2018
Time: 4:05 p.m. Eastern Daylight Time
Location: Grand Hyatt New York, NYC
Webcast:

https://cc.talkpoint.com/morg007/091218a_as/?entity=53_0XGPDH2

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors + News Section.